Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Journal of Neuroscience Research
|
March 30, 2004
PACAP promotes neural stem cell proliferation in adult mouse brain
Alex Mercer, Harriet Rönnholm, Johan Holmberg, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 22, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
Hiddo Jl Heerspink, Brad H Rovin, Radko Komers, et al.
Journal of Neuroscience Research
|
September 7, 2007
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, et al.
Clinical Kidney Journal
|
July 11, 2024
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort
Eleni Stamellou, Jennifer Nadal, Bruce Hendry, et al.
Journal of the American Society of Nephrology : JASN
|
August 4, 2025
Authors' Reply: Questions Regarding the Analysis of Long-Term Outcomes in Nephrotic Syndrome
David Pitcher, Bruce Hendry, Alex Mercer, et al.
Journal of the American Society of Nephrology : JASN
|
April 17, 2025
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
Clinical Kidney Journal
|
August 16, 2024
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort
Eleni Stamellou, Jennifer Nadal, Bruce Hendry, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
April 13, 2023
Long-Term Outcomes in IgA Nephropathy
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
Lancet (London, England)
|
April 4, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Hiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, et al.
Lancet (London, England)
|
April 2, 2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Bengt C Fellström, Jonathan Barratt, Heather Cook, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Journal of Neuroscience Research
|
March 30, 2004
PACAP promotes neural stem cell proliferation in adult mouse brain
Alex Mercer, Harriet Rönnholm, Johan Holmberg, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 22, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
Hiddo Jl Heerspink, Brad H Rovin, Radko Komers, et al.
Journal of Neuroscience Research
|
September 7, 2007
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, et al.
Clinical Kidney Journal
|
July 11, 2024
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort
Eleni Stamellou, Jennifer Nadal, Bruce Hendry, et al.
Journal of the American Society of Nephrology : JASN
|
August 4, 2025
Authors' Reply: Questions Regarding the Analysis of Long-Term Outcomes in Nephrotic Syndrome
David Pitcher, Bruce Hendry, Alex Mercer, et al.
Journal of the American Society of Nephrology : JASN
|
April 17, 2025
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
Clinical Kidney Journal
|
August 16, 2024
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort
Eleni Stamellou, Jennifer Nadal, Bruce Hendry, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
April 13, 2023
Long-Term Outcomes in IgA Nephropathy
David Pitcher, Fiona Braddon, Bruce Hendry, et al.
Lancet (London, England)
|
April 4, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Hiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, et al.
Lancet (London, England)
|
April 2, 2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Bengt C Fellström, Jonathan Barratt, Heather Cook, et al.
Page
of 3